Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Akers Biosciences starts China sales after HIT test approval

Initial sales are anticipated prior to the end of the first quarter
Akers Biosciences starts China sales after HIT test approval
HIT is a potentially fatal allergy to Heparin, a widely used blood thinning drug.

Akers Biosciences (NASDAQ:AKER  LON:AKER) has started to supply its test for Heparin allergy or HIT into China after it was cleared for medical use in the country.

NovoTek Therapeutics, its Chinese distributor, has placed a US$2.5mln order that will be fulfilled in tranches throughout 2016.

Beijing-based Novotek has exclusive sales and marketing rights for PIFA Heparin/PF4 Rapid Assay products in China.

Initial sales are anticipated prior to the end of the first quarter. 

HIT is a potentially fatal allergy to Heparin, a widely used blood thinning drug. The allergy reverses the effect of Heparin and turns it into a clotting agent, which is especially dangerous for patients undergoing major cardiac, orthopaedic or other surgical procedures.

Between 1% and 5% of those patients using Heparin receive a HIT diagnosis. 

The PIFA Heparin/PF4 Rapid Assay and PIFA PLUSS PF4 version (which tests whole blood) are the first and only tests of any kind for PF4 antibodies (associated heparin-induced thrombocytopenia (HIT)) available in China, Akers said.

The rapid assay test is also the only one so far approved in the US, where the company hopes to have 500 hospitals prescribing it by the end of 2016.

Raymond Akers Jr, executive chairman, added: "The China FDA's approval of our test paves the way for Akers Bio and NovoTek to establish the PIFA Heparin/PF4 Rapid Assay devices as the gold standard for HIT testing throughout China."

He added that NovoTek will now set up a complete solution to manage HIT in the Chinese healthcare system through exclusive licences both for the test and as a treatment for patients diagnosed with HIT.

Broker finncap said that against a sales base of US$4mln, Novotek's represents a substantial order.

There are estimated to be 12mln patients who are prescribed Heparin in China and with 1-5% of patients developing HIT, the potential demand is for up to 0.6mln tests per annum, it adds.

 

 

 

PhilW.jpg
Why Invest In Akers Biosciences, Inc.? Read More Here

Register here to be notified of future AKR Company articles
View full AKR profile

Akers Biosciences, Inc. Timeline

Related Articles

cells_56ab78cfbeec5.jpg
January 29 2016
A return to Nasdaq and ongoing commercial success promises to address a significant disconnect in the valuation of Pressure Bioscience...
1-Operation.jpg
April 12 2016
Deltex’s overseas sales are booming but its previously dominant NHS revenues are dropping off
AZN3.jpg
November 10 2016
Patent safeguards the technology at the heart of the device that offers a non-invasive method of monitoring diabetes.

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.